Equities Analysts Set Expectations for TYRA FY2026 Earnings

Key Points

• HC Wainwright raised Tyra Biosciences’ FY2026 EPS forecast to a loss of $2.60 per share from $2.86, while maintaining a “Buy” rating and $29 price target.
• Tyra reported a quarterly loss of $0.69 per share, missing the $0.65 consensus estimate. Despite the miss, analysts broadly remain positive, with a “Moderate Buy” consensus rating and an average price target of $46.89.
• Shares opened at $23.23, down 9.2%, while institutional investors and hedge funds own 84.14% of the stock; major new positions were reported from Jupiter Topco and BlackRock.

Tyra Biosciences, Inc. (NASDAQ:TYRA - Free Report) - Equities researchers at HC Wainwright raised their FY2026 earnings per share (EPS) estimates for Tyra Biosciences in a report issued on Tuesday, September 22nd. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings of ($2.60) per share for the year, up from their prior forecast of ($2.86). HC Wainwright currently has a "Buy" rating and a $29.00 target price on the stock. The consensus estimate for Tyra Biosciences' current full-year earnings is ($2.73) per share. HC Wainwright also issued estimates for Tyra Biosciences' Q4 2026 earnings at ($0.62) EPS, Q1 2027 earnings at ($0.56) EPS, Q2 2027 earnings at ($0.57) EPS, Q3 2027 earnings at ($0.57) EPS, Q4 2027 earnings at ($0.58) EPS and FY2027 earnings at ($2.27) EPS.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.65) by ($0.04).

Other equities analysts also recently issued reports about the stock. Oppenheimer reissued an "outperform" rating and issued a $40.00 price target (down from $50.00) on shares of Tyra Biosciences in a research note on Tuesday. Wedbush reaffirmed an "outperform" rating and set a $53.00 price objective on shares of Tyra Biosciences in a research note on Thursday, September 10th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Tyra Biosciences in a report on Thursday, September 10th. Jefferies Financial Group restated a "buy" rating and set a $42.00 target price on shares of Tyra Biosciences in a report on Wednesday, August 5th. Finally, Bank of America upped their price target on Tyra Biosciences from $37.00 to $42.00 and gave the company a "buy" rating in a research report on Wednesday, June 10th. Twelve analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $46.89.

Tyra Biosciences Stock Down 9.2%

Shares of TYRA opened at $23.23 on Thursday. Tyra Biosciences has a 52-week low of $12.40 and a 52-week high of $40.65. The stock has a market cap of $1.39 billion, a PE ratio of -9.68 and a beta of 0.73. The firm's fifty day moving average is $27.19 and its two-hundred day moving average is $31.33.

Hedge Funds Weigh In On Tyra Biosciences

Institutional investors and hedge funds have recently bought and sold shares of the company. Jupiter Topco LLC purchased a new stake in shares of Tyra Biosciences during the 2nd quarter valued at approximately $139,161,000. Janus Henderson Group PLC grew its position in Tyra Biosciences by 32.5% in the first quarter. Janus Henderson Group PLC now owns 3,890,589 shares of the company's stock worth $148,867,000 after acquiring an additional 955,147 shares during the period. BlackRock Inc. acquired a new stake in Tyra Biosciences during the second quarter worth $96,841,000. 5AM Venture Management LLC increased its stake in Tyra Biosciences by 9.6% during the fourth quarter. 5AM Venture Management LLC now owns 1,029,298 shares of the company's stock worth $27,060,000 after acquiring an additional 90,000 shares during the last quarter. Finally, Jennison Associates LLC purchased a new stake in Tyra Biosciences in the first quarter valued at $24,222,000. 84.14% of the stock is currently owned by institutional investors and hedge funds.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc is a clinical-stage biotechnology company focused on developing precision medicines for diseases with limited treatment options. The company uses its proprietary SNÅP platform to design small-molecule therapies intended to selectively target disease-driving genetic alterations while addressing resistance mechanisms that can reduce the effectiveness of existing treatments.

Tyra's lead programs are directed at fibroblast growth factor receptor (FGFR) biology. TYRA-300 is an oral, selective FGFR3 inhibitor being developed for conditions including FGFR3-altered urothelial cancer and achondroplasia, a genetic skeletal disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.